Thrombopoietin Protects the Brain and Improves Sensorimotor Functions: Reduction of Stroke-induced MMP-9 Upregulation and Blood-brain Barrier Injury

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2010 Sep 30

PMID 20877384

Citations 25

Authors

Jin Zhou

Jie Li

Daniel M Rosenbaum

Frank C Barone

Affiliations

Soon will be listed here.

Abstract

This study was conducted to determine the protective efficacy and mechanisms of thrombopoietin (TPO) intervention in experimental focal stroke. Male rats underwent 2 hours of left middle cerebral artery occlusion (MCAO) followed by 22 hours of reperfusion. Vehicle or TPO (0.03 to 1.00 μg/kg) was administered intravenously immediately after reperfusion. Brain infarct and swelling, neurologic deficits, matrix metalloproteinase-9 (MMP-9), tissue inhibitor of metalloproteinase-1 (TIMP-1), TPO and c-Mpl (TPO receptor) mRNA, MMP-9 enzyme activity and protein expression, and the integrity of the blood-brain barrier (BBB) were subsequently measured. MCAO reperfusion produced a large infarct and swelling after stroke. Thrombopoietin significantly reduced these in a dose-dependent manner. The most effective TPO dose, 0.1 μg/kg, when administrated immediately or 2 hours after reperfusion, significantly reduced infarct and swelling and ameliorated neurologic deficits after stroke. Stroke-induced increases in cortical MMP-9 mRNA, enzyme activity and protein expression, TIMP-1 mRNA, and Evans blue extravasation were reduced by TPO intervention. Thrombopoietin did not alter cortical TPO or c-Mpl mRNA expression, blood pressure, heart rate, blood hematocrit, or platelets. This is the first demonstration of TPO's efficacy in reducing ischemic brain injury and improving functional outcome, partly by inhibiting the stroke-induced increase in MMP-9 and the early, negative effects on the BBB.

Citing Articles

The link between BDNF and platelets in neurological disorders.

Bouhaddou N, Mabrouk M, Atifi F, Bouyahya A, Zaid Y Heliyon. 2024; 10(21):e39278.

PMID: 39568824 PMC: 11577193. DOI: 10.1016/j.heliyon.2024.e39278.

A review on the functional characteristics of the c-Myeloproliferative Leukaemia (c-MPL) gene and its isoforms.

Hussain M, Das S, Kulkarni M, Laha S Cell Oncol (Dordr). 2024; 47(5):1607-1626.

PMID: 39283476 DOI: 10.1007/s13402-024-00988-w.

Early peripheral blood gene expression associated with good and poor 90-day ischemic stroke outcomes.

Amini H, Knepp B, Rodriguez F, Jickling G, Hull H, Carmona-Mora P J Neuroinflammation. 2023; 20(1):13.

PMID: 36691064 PMC: 9869610. DOI: 10.1186/s12974-022-02680-y.

Correlation between thrombopoietin and inflammatory factors, platelet indices, and thrombosis in patients with sepsis: A retrospective study.

Xu W, Mo L, Shi M, Rao H, Zhan X, Yang M World J Clin Cases. 2022; 10(13):4072-4083.

PMID: 35665097 PMC: 9131241. DOI: 10.12998/wjcc.v10.i13.4072.

Neuroprotective effects of long noncoding RNAs involved in ischemic postconditioning after ischemic stroke.

Ma W, Li C, Zhang S, Zang C, Yang J, Wu Z Neural Regen Res. 2021; 17(6):1299-1309.

PMID: 34782575 PMC: 8643058. DOI: 10.4103/1673-5374.327346.

References

Li B, Dai W . Thrombopoietin and neurotrophins share a common domain. Blood. 1995; 86(4):1643-4. View

Wang X, Barone F, White R, Feuerstein G . Subtractive cloning identifies tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) increased gene expression following focal stroke. Stroke. 1998; 29(2):516-20. DOI: 10.1161/01.str.29.2.516. View

Belayev L, Khoutorova L, Zhao W, Vigdorchik A, Belayev A, Busto R . Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats. Stroke. 2005; 36(5):1071-6. DOI: 10.1161/01.STR.0000160753.36093.da. View

Jasmin J, Malhotra S, Dhallu M, Mercier I, Rosenbaum D, Lisanti M . Caveolin-1 deficiency increases cerebral ischemic injury. Circ Res. 2007; 100(5):721-9. DOI: 10.1161/01.RES.0000260180.42709.29. View

Zhao B, Wang S, Kim H, Storrie H, Rosen B, Mooney D . Role of matrix metalloproteinases in delayed cortical responses after stroke. Nat Med. 2006; 12(4):441-5. DOI: 10.1038/nm1387. View

Wang L, Zhang Z, Wang Y, Zhang R, Chopp M . Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke. 2004; 35(7):1732-7. DOI: 10.1161/01.STR.0000132196.49028.a4. View

Legos J, Lenhard S, Haimbach R, Schaeffer T, Bentley R, McVey M . SB 234551 selective ET(A) receptor antagonism: perfusion/diffusion MRI used to define treatable stroke model, time to treatment and mechanism of protection. Exp Neurol. 2008; 212(1):53-62. DOI: 10.1016/j.expneurol.2008.03.011. View

Belayev L, Busto R, Zhao W, Ginsberg M . Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 1996; 739(1-2):88-96. DOI: 10.1016/s0006-8993(96)00815-3. View

Zhou J, Pavel J, Macova M, Yu Z, Imboden H, Ge L . AT1 receptor blockade regulates the local angiotensin II system in cerebral microvessels from spontaneously hypertensive rats. Stroke. 2006; 37(5):1271-6. DOI: 10.1161/01.STR.0000217404.64352.d7. View

10.

Zhou J, Ando H, Macova M, Dou J, Saavedra J . Angiotensin II AT1 receptor blockade abolishes brain microvascular inflammation and heat shock protein responses in hypertensive rats. J Cereb Blood Flow Metab. 2005; 25(7):878-86. DOI: 10.1038/sj.jcbfm.9600082. View

11.

Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K . Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12):e647-56. DOI: 10.1161/STROKEAHA.109.564872. View

12.

Levin J, Cocault L, Demerens C, Challier C, Pauchard M, Caen J . Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response. Blood. 2001; 98(4):1019-27. DOI: 10.1182/blood.v98.4.1019. View

13.

Romanic A, White R, Arleth A, Ohlstein E, Barone F . Matrix metalloproteinase expression increases after cerebral focal ischemia in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke. 1998; 29(5):1020-30. DOI: 10.1161/01.str.29.5.1020. View

14.

Kondo T, Reaume A, Huang T, Carlson E, Murakami K, Chen S . Reduction of CuZn-superoxide dismutase activity exacerbates neuronal cell injury and edema formation after transient focal cerebral ischemia. J Neurosci. 1997; 17(11):4180-9. PMC: 6573543. View

15.

ROSENBAUM D, Rosenbaum P, Gupta H, Singh M, Aggarwal A, Hall D . The role of the p53 protein in the selective vulnerability of the inner retina to transient ischemia. Invest Ophthalmol Vis Sci. 1998; 39(11):2132-9. View

16.

Ding Y, Li J, Lai Q, Rafols J, Luan X, Clark J . Motor balance and coordination training enhances functional outcome in rat with transient middle cerebral artery occlusion. Neuroscience. 2004; 123(3):667-74. DOI: 10.1016/j.neuroscience.2003.08.031. View

17.

Del Zoppo G, Saver J, Jauch E, Adams Jr H . Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40(8):2945-8. PMC: 2782817. DOI: 10.1161/STROKEAHA.109.192535. View

18.

Pacary E, Petit E, Bernaudin M . Erythropoietin, a cytoprotective and regenerative cytokine, and the hypoxic brain. Neurodegener Dis. 2006; 3(1-2):87-93. DOI: 10.1159/000092098. View

19.

Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M . Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002; 8(8):495-505. PMC: 2040012. View

20.

Eguchi M, Masuda H, Kwon S, Shirakura K, Shizuno T, Ito R . Lesion-targeted thrombopoietin potentiates vasculogenesis by enhancing motility and enlivenment of transplanted endothelial progenitor cells via activation of Akt/mTOR/p70S6kinase signaling pathway. J Mol Cell Cardiol. 2008; 45(5):661-9. DOI: 10.1016/j.yjmcc.2008.08.002. View